SPYH:XETRA:XETRA-SPDR® MSCI Europe Health Care UCITS ETF (EUR)

ETF | Others |

Last Closing

USD 235.9

Change

-1.45 (-0.61)%

Market Cap

USD 0.66B

Volume

87.00

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

NA

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-09-18 )

Largest Industry Peers for Others

Symbol Name Price(Change) Market Cap
XM1D:XETRA Xtrackers MSCI Japan UCITS ETF..

-0.47 (-0.93%)

USD 484.40B
LCUJ:XETRA Lyxor Core MSCI Japan (DR) UCI..

-0.15 (-0.92%)

USD 191.96B
PRAJ:XETRA Amundi Index Solutions - Amund..

-0.27 (-1.00%)

USD 177.46B
PR1J:XETRA Amundi Prime Japan UCITS ETF D..

-0.26 (-0.92%)

USD 177.46B
XDJP:XETRA Xtrackers Nikkei 225 UCITS ETF..

-0.16 (-0.65%)

USD 157.79B
8R80:XETRA Amundi Index Solutions - Amund..

-1.72 (-1.23%)

USD 98.29B
JARI:XETRA Amundi Index Solutions - Amund..

-0.62 (-1.35%)

USD 98.25B
UIM5:XETRA UBS (Lux) Fund Solutions - MSC..

-0.42 (-0.83%)

USD 85.64B
SXR8:XETRA iShares Core S&P 500 UCITS ETF..

-2.62 (-0.49%)

USD 80.38B
FRCJ:XETRA UBS MSCI Japan Socially Respon..

-0.26 (-1.15%)

USD 79.79B

ETFs Containing SPYH:XETRA

N/A

Market Performance

  Market Performance vs. Industry/Classification (Others) Market Performance vs. Exchange
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 17.25% 89% A- 87% B+
Dividend Return N/A N/A N/A N/A N/A
Total Return 17.25% 89% A- 85% B
Trailing 12 Months  
Capital Gain 13.91% 62% D 64% D
Dividend Return N/A N/A N/A N/A N/A
Total Return 13.91% 61% D- 62% D
Trailing 5 Years  
Capital Gain 60.65% 79% B- 78% C+
Dividend Return N/A N/A N/A N/A N/A
Total Return 60.65% 79% B- 76% C+
Average Annual (5 Year Horizon)  
Capital Gain 8.54% 66% D+ 64% D
Dividend Return 8.54% 65% D 62% D
Total Return N/A N/A N/A N/A N/A
Risk Return Profile  
Volatility (Standard Deviation) 8.31% 66% D+ 73% C
Risk Adjusted Return 102.79% 97% N/A 97% N/A
Market Capitalization 0.66B 70% C- 62% D

Annual Financials (EUR)

Quarterly Financials (EUR)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

What to not like:

There is nothing we particularly dislike